Alexander C. Egilman

Author

Yale University ORCID

Also Known As

Alexander C Egilman, Alexander C. Egilman, Alexander Egilman

Publications

528

Citations

H-Index

Concepts

All Affiliations

Yale University Brigham and Women's Hospital Yale New Haven Hospital Yale New Haven Health System Harvard University

About

Alexander C. Egilman is an author at Yale University specializing in medicine, health economics, and health services competition.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	128
2	Public Health	2	2	110
3	Health Policy	2	2	110
4	Management	1	1	10
5	Marketing	1	1	10

Alexander C. Egilman

Publications

360

Citations

H-Index

Page 1

	Year	Citations
Trends in Prescription Drug Launch Prices, 2008-2021 Benjamin N. Rome, Alexander C. Egilman, Aaron S. Kesselheim JAMA Population Health SciencesPharmacotherapyBrand-name Prescription DrugsClinical EpidemiologyClinical Trials	2022	100
Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis Joshua D. Wallach, Alexander C. Egilman, Sanket S. Dhruva, BMJ	2018	69
Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022 Benjamin N. Rome, Sarosh Nagar, Alexander C. Egilman, JAMA Health Forum	2023	42
Biomedical journal speed and efficiency: a cross-sectional pilot survey of author experiences Joshua D. Wallach, Alexander C. Egilman, Anand Gopal, Research Integrity and Peer Review	2018	34
Speed, Evidence, and Safety Characteristics of Vaccine Approvals by the US Food and Drug Administration Jeremy Puthumana, Alexander C. Egilman, Audrey D. Zhang, JAMA Internal Medicine	2020	29
Transparency of Regulatory Data across the European Medicines Agency, Health Canada, and US Food and Drug Administration Alexander C. Egilman, Amy Kapczynski, Margaret E. McCarthy, The Journal of Law Medicine & Ethics	2021	25
Added Therapeutic Benefit of Top-Selling Brand-name Drugs in Medicare Alexander C. Egilman, Benjamin N. Rome, Aaron S. Kesselheim JAMA	2023	20
Timeliness of Postmarket Studies for New Pharmaceuticals Approved Between 2009 and 2012: a Cross-Sectional Analysis Joshua D. Wallach, Alexander C. Egilman, Joseph S. Ross, Journal of General Internal Medicine Postmarket StudiesHealth EconomicsPharmacologyPharmacoeconomicsPharmacotherapy	2018	18
Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017 Joshua J. Skydel, Alexander C. Egilman, Joshua D. Wallach, JAMA Health Forum	2022	13
Frequency of Approval and Marketing of Biosimilars With a Skinny Label and Associated Medicare Savings Alexander C. Egilman, Victor L. Van de Wiele, Benjamin N. Rome, JAMA Internal Medicine Skinny-label BiosimilarsConsumer ResearchHealth Care FinanceAssociated Medicare SavingsBiobank	2022	10

Page 1